Abstract
Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Current Pharmaceutical Design
Title:Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Volume: 23 Issue: 8
Author(s): Paolo Poggio*, Gianluca Folesani, Giuseppe M. Raffa, Paola Songia, Vincenzo Valenti, Veronika Myasoedova and Alessandro Parolari
Affiliation:
- Laboratory of Biochemical Cardiology Unit for the Study of Aortic, Valvular and Coronary Pathologies Centro Cardiologico Monzino, IRCCS Via Carlo Parea 4, 20138 Milan,Italy
Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Abstract: Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Export Options
About this article
Cite this article as:
Poggio Paolo*, Folesani Gianluca, Raffa M. Giuseppe, Songia Paola, Valenti Vincenzo, Myasoedova Veronika and Parolari Alessandro, Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis, Current Pharmaceutical Design 2017; 23 (8) . https://dx.doi.org/10.2174/1381612823666161123144534
DOI https://dx.doi.org/10.2174/1381612823666161123144534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun
Current Pharmaceutical Design Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design From Molecular Footprints of Disease to New Therapeutic Interventions in Diabetic Nephropathy: A Detective Story
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Polycystic Ovary Syndrome and Infertility: From Molecular Perspective
Current Women`s Health Reviews Current Status of Ethosomes and Elastic Liposomes in Dermal and Transdermal Drug Delivery
Current Pharmaceutical Design Role of β 2-Adrenoceptor Activation in Sepsis-Induced Renal Inflammation
Current Immunology Reviews (Discontinued) Nanosystems for Skin Delivery: From Drugs to Cosmetics
Current Drug Metabolism Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment
Current Vascular Pharmacology The Role of Matrix Gla Protein (MGP) in Vascular Calcification
Current Medicinal Chemistry Effects of Vitamin E and C on Placental Oxidative Stress: An In Vitro Evidence for the Potential Therapeutic or Prophylactic Treatment of Preeclampsia
Medicinal Chemistry Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat
Current Diabetes Reviews Current Approaches to Prevention of Contrast Induced Acute Kidney Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine The Role of Pericytes in Neurovascular Unit: Emphasis on Stroke
Current Drug Targets Editorial (Thematic Issue: Switching to Biological Agents in Autoimmune and Autoinflammatory Disorders: Current Targets and Therapy)
Current Medicinal Chemistry Effects of Minor Compounds of Edible Oils on Human Health
Current Nutrition & Food Science Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Current Pediatric Reviews The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology